ClinicalTrials.gg

Program

navlimetostat

Also written as “Navlimetostat”, “BMS-986504” and “[14C]Navlimetostat”.

Its studies are mostly in Lung Neoplasms · Brain Neoplasms · Carcinoma, Non-Small-Cell Lung · Mesothelioma · Pancreatic Neoplasms, led by Bristol-Myers Squibb.

Furthest: phase 3, since Jul 3, 202510 company-led studies, 10 open or runningNext primary completion: Dec 5, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb1010 open or runningphase 3since Jul 3, 2025Feb 1, 2022Dec 5, 2026phase 1 · NCT07777133
  • Named in Bristol-Myers Squibb’s own pipeline as navlimetostat, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 1, 2022First study: phase 1 study in MesotheliomaFirst studyNCT05245500 · 336 planned · United States
  2. Nov 1, 2024Phase 1 study in Advanced Solid Tumors With Homozygous MTAP DeletionNCT06672523 · 8 planned · Hungary, Spain
  3. Feb 27, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06855771 · 182 planned · United States, Australia, China and more
  4. Jul 3, 20252 phase 3 studiesNCT07063745, NCT07076121
  5. Jul 21, 2025Phase 1 study in Advanced Solid TumorsNCT07077434 · 32 planned · China, Japan
  6. Mar 20, 2026Phase 2 study in Brain NeoplasmsNCT07492680 · 254 planned · United States, Belgium, Canada and more
  7. Apr 16, 2026Phase 1 study in Healthy ParticipantsNCT07544628 · 64 planned · United States
  8. Aug 18, 20262 phase 1 studiesNCT07777133, NCT07800897

Ahead

  1. Nov 2, 2026Primary completion: phase 1 study in Healthy ParticipantsNCT07544628
  2. Dec 5, 2026Primary completion: phase 1 study in Healthy Female ParticipantsNCT07777133
  3. Jan 19, 2027Primary completion: phase 1 study in Advanced Solid TumorsNCT07077434
  4. Mar 25, 2027Primary completion: phase 1 study in Healthy Female AdultsNCT07800897

TargetBeta

“An orally bioavailable methylthioadenosine (MTA)-selective inhibitor of the protein arginine methyltransferase 5 (PRMT5), with potential antineoplastic activity. Upon oral administration, PRMT5 inhibitor BMS-986504 targets, binds to and inhibits PRMT5 that is bound to MTA, a complex that is eleva…”NCIt, read by Claude
“An orally bioavailable methylthioadenosine (MTA)-selective inhibitor of the protein arginine methyltransferase 5 (PRMT5), ”NCIt, by rule

Other programs on PRMT5

ProgramCompanyFurthest phaseStudies
PRMT5 Inhibitor AZD3470AstraZenecaphase 22
JBI-778rulejubilant-therapeutics-india-limitedphase 22
PRMT5 Inhibitor TNG456ruletango-therapeutics-incphase 21
PRMT5 Inhibitor BAY 3713372ruleBayerphase 21
onametostatruleJohnson & Johnsonphase 12
PRMT5 Inhibitor SH3765ruleNanjing Sanhome Pharmaceuticalphase 12
PRMT5 Inhibitor BGB-58067ruleBeOne Medicinesphase 12
PRMT5 Inhibitor IDE892ruleideaya-biosciencesphase 11
PEP08rulepharmaenginephase 11

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07800897Healthy Female Adults · Canada1RecruitingMar 25, 202780
NCT07777133Healthy Female Participants · United States, Netherlands1RecruitingDec 5, 20266
NCT07544628Healthy Participants · United States1RecruitingNov 2, 202664
NCT07492680Brain Neoplasms · United States, Belgium, Canada and more2RecruitingAug 15, 2028254
NCT07077434Advanced Solid Tumors · China, Japan1RecruitingJan 19, 202732
NCT07076121Pancreatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingMay 3, 2029470
NCT07063745Lung Neoplasms · United States, Argentina, Australia and more3RecruitingAug 12, 2031590
NCT06855771Carcinoma, Non-Small-Cell Lung · United States, Australia, China and more2RecruitingDec 29, 2028182
NCT06672523Advanced Solid Tumors With Homozygous MTAP Deletion · Hungary, Spain1RecruitingOct 25, 20278
NCT05245500Mesothelioma · United States1RecruitingDec 10, 2027336

How it is read

Names in the registry

  • “Navlimetostat”, 5 entries
  • “BMS-986504”, 4 entries
  • “[14C]Navlimetostat”, 1 entry
  • “MRTX1719”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.